Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced it has been ranked 416th in revenue growth among all companies in the U.S. and Canada for revenue growth between 2018 and 2021 on Deloitte’s Technology Fast 500. Zynex’s revenues grew 308% over that period, with 2021 revenue reaching $130.3 million. The company estimates 2022 revenue between $157.4 and $160.4 million. The 2022 Deloitte Technology Fast 500 list can be found at www.fast500.com.
“We are honored by the recognition of Zynex’s revenue growth by Deloitte’s Technology Fast 500 for the fourth year in a row,” said Thomas Sandgaard, CEO and founder of Zynex Inc. “I am extremely proud of our team’s accomplishments in driving revenue growth year-after-year, and believe this distinguished award reflects our commitment to long term market share gains and strategic goal execution.”
“This year’s Technology Fast 500 list is a true reflection of some of today’s most determined and inspiring pioneers who have prospered by anticipating what’s next, understanding what’s needed to succeed and driving creativity forward,” said Christie Simons, partner, Deloitte & Touche LLP and industry leader for technology, media and telecommunications within Deloitte’s audit & assurance practice. “Representing all facets of technology, the winners have shown they not only have the vision but can also expertly manage their companies through rapid growth. We congratulate each winner on their and impressive achievements.”
Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!